Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration

von Behring, 1901 Orange, 2006, Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, J Allergy Clin Immunol, 117, S525, 10.1016/j.jaci.2006.01.015 Gardulf, 1995, Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs, Lancet, 345, 365, 10.1016/S0140-6736(95)90346-1 Gardulf, 2007, Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route, BioDrugs, 21, 105, 10.2165/00063030-200721020-00005 Moore, 2008, Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century, Ann Allergy Asthma Immunol, 101, 114, 10.1016/S1081-1206(10)60197-4 Ochs, 2006, Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases, J Clin Immunol, 26, 265, 10.1007/s10875-006-9021-7 Pharmacopoeia 6.6, 2010 Cohn, 1946, Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of tissues and fluids, J Am Chem Soc, 68, 459, 10.1021/ja01207a034 Kistler, 1962, Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier, Vox Sang, 7, 414, 10.1111/j.1423-0410.1962.tb03274.x Stucki, 2008, Investigations of prion and virus safety of a new liquid IVIG product, Biologicals, 36, 239, 10.1016/j.biologicals.2008.01.004 2003 Cramer, 2009, Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with l-proline, Vox Sang, 96, 219, 10.1111/j.1423-0410.2008.01143.x Bleeker, 1987, An animal model for the detection of hypotensive side effects of immunoglobulin preparations, Vox Sang, 52, 281, 10.1111/j.1423-0410.1987.tb04894.x Daugherty, 2006, Formulation and delivery issues for monoclonal antibody therapeutics, Adv Drug Deliv Rev, 58, 686, 10.1016/j.addr.2006.03.011 Knezevic-Maramica, 2003, Intravenous immune globulins: an update for clinicians, Transfusion, 43, 1460, 10.1046/j.1537-2995.2003.00519.x Rosenberg, 2006, Effects of protein aggregates: an immunologic perspective, AAPS J, 8, E501, 10.1208/aapsj080359 Hagan, 2010, Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency, J Clin Immunol, 30, 734, 10.1007/s10875-010-9423-4 Bolli, 2010, L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions, Biologicals, 38, 150, 10.1016/j.biologicals.2009.09.002 Dyer, 2006, Characterisation of photo-oxidation products within photoyellowed wool proteins: tryptophan and tyrosine derived chromophores, Photochem Photobiol Sci, 5, 698, 10.1039/b603030k Qi, 2009, Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form, J Pharm Sci, 98, 3117, 10.1002/jps.21617 Kroez, 2003, Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation, Biologicals, 31, 277, 10.1016/j.biologicals.2003.09.001 Ballow, 2007, Safety of IGIV therapy and infusion-related adverse events, Immunol Res, 38, 122, 10.1007/s12026-007-0003-5 Berger, 1982, High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy, J Am Med Assoc, 247, 2824, 10.1001/jama.1982.03320450058038 Berger, 2004, Subcutaneous immunoglobulin replacement in primary immunodeficiencies, Clin Immunol, 112, 1, 10.1016/j.clim.2004.02.002 Wang, 1999, Instability, stabilization, and formulation of liquid protein pharmaceuticals, Int J Pharm, 185, 129, 10.1016/S0378-5173(99)00152-0 Samuel, 2000, Proline inhibits aggregation during protein refolding, Protein Sci, 9, 344, 10.1110/ps.9.2.344